2 news items
Cue Biopharma Presents Updated Data From Phase 1 Trial of CUE-101 In Recurrent/Metastatic HPV+ Head And Neck Cancer At ASCO 2024
CUE
4 Jun 24
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
CUE
8 Apr 24
CUE-101 in combination with pembrolizumab in 1L R/M HNSCC showed an overall response rate (ORR
- Prev
- 1
- Next